Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ArQule Inc. ARQL

Healthcare Biotechnology
Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Recent & Breaking News (NDAQ:ARQL)

ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference

GlobeNewswire September 8, 2015

ArQule Reports Second Quarter 2015 Financial Results

GlobeNewswire August 5, 2015

ArQule to Report Second Quarter 2015 Financial Results on August 5, 2015

Business Wire July 29, 2015

ArQule Announces Interim Phase 2 Study Results for Tivantinib in Combination with Cetuximab in Patients with MET-High, KRAS Wild Type Colorectal Cancer Presented at ESMO World Congress on Gastrointestinal Cancer 2015

Business Wire July 6, 2015

ArQule Appoints Robert J. Weiskopf as Chief Financial Officer

Business Wire June 1, 2015

ArQule Announces Data Presentations with Tivantinib and ARQ 087 to Be Featured at ASCO 2015

Business Wire May 29, 2015

ArQule, Inc. to Present at Jefferies 2015 Global Healthcare Conference

Business Wire May 27, 2015

ArQule and Beryllium Announce Collaborative Research and Development Agreement

Business Wire May 5, 2015

ArQule to Report First Quarter 2015 Financial Results on May 6, 2015

Business Wire April 29, 2015

ArQule Announces Data Presentations with ARQ 087, Inhibitor of FGFR, at AACR

Business Wire April 21, 2015

ArQule, Inc. to Present at 14th Annual Needham Healthcare Conference

Business Wire April 7, 2015

ArQule Reports Fiscal 2014 Year End and Fourth Quarter Results

Business Wire March 4, 2015

ArQule to Report Fiscal 2014 Financial Results on March 4, 2015

Business Wire February 25, 2015

ArQule, Inc. to Present at 2015 RBC Capital Markets' Global Healthcare Conference

Business Wire February 17, 2015

ArQule, Inc. to Present at Leerink Global Healthcare Conference

Business Wire February 4, 2015

ArQule Announces Data Presentations with Pipeline Products to Be Featured at 26th EORTC-NCI-AACR Symposium

Business Wire November 13, 2014

ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome

Business Wire November 11, 2014

ArQule Announces Positive Top-Line Results of NIH-Sponsored Phase 2 Trial of Tivantinib in Prostate Cancer

Business Wire November 10, 2014

ArQule Announces Third Quarter Fiscal 2014 Results

Business Wire November 10, 2014

ArQule to Report Third Quarter 2014 Financial Results on November 10, 2014

Business Wire November 3, 2014